Shield Therapeutics Plc Stock Current Asset
| SHIEF Stock | USD 0.1 0.0008 0.82% |
Fundamental analysis of Shield Therapeutics allows traders to better anticipate movements in Shield Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Shield |
Shield Therapeutics plc OTC Stock Current Asset Analysis
Shield Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Shield Therapeutics plc has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Shield Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shield Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Shield Therapeutics could also be used in its relative valuation, which is a method of valuing Shield Therapeutics by comparing valuation metrics of similar companies.Shield Therapeutics is currently under evaluation in current asset category among its peers.
Shield Fundamentals
| Return On Equity | -0.57 | |||
| Return On Asset | -0.34 | |||
| Operating Margin | (7.83) % | |||
| Current Valuation | 18.31 M | |||
| Shares Outstanding | 585.67 M | |||
| Shares Owned By Insiders | 42.23 % | |||
| Shares Owned By Institutions | 13.58 % | |||
| Price To Book | 0.75 X | |||
| Price To Sales | 7.37 X | |||
| Revenue | 1.52 M | |||
| Gross Profit | 539 K | |||
| EBITDA | (17.35 M) | |||
| Net Income | (19.34 M) | |||
| Cash And Equivalents | 2.4 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 156 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 2.60 X | |||
| Book Value Per Share | 0.15 X | |||
| Cash Flow From Operations | (16.74 M) | |||
| Earnings Per Share | (0.11) X | |||
| Number Of Employees | 15 | |||
| Beta | 1.1 | |||
| Market Capitalization | 51.48 M | |||
| Total Asset | 44.41 M | |||
| Net Asset | 44.41 M |
About Shield Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shield Therapeutics plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shield Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shield Therapeutics plc based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Shield OTC Stock
Shield Therapeutics financial ratios help investors to determine whether Shield OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shield with respect to the benefits of owning Shield Therapeutics security.